Tolerance and immunological response in human immunodeficiency virus (HIV) seropositive individuals after NR100063 supplementation

Submission date	Recruitment status No longer recruiting	Prospectively registered		
05/07/2010		Protocol		
Registration date	Overall study status Completed	Statistical analysis plan		
29/07/2010		[X] Results		
Last Edited	Condition category	Individual participant data		
21/12/2011	Infections and Infestations			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Andrea Gori

Contact details

Ospedale Luigi Sacco Via Giovanni Battista Grassi, 74 Milano Italy 20157 andrea.gori@unimib.it

Additional identifiers

Protocol serial number 100063

Study information

Scientific Title

Tolerance and immunological response in human immunodeficiency virus (HIV) seropositive individuals after NR100063 supplementation: a randomised double-blind placebo-controlled three-arm parallel study

Acronym

COPA

Study objectives

H0: No difference between Group 1 (Copa 2x dose), Group 2 (Copa 1x dose) and the control group on variable

H1: At least two of the three treatments differ from each other

Ethics approval required

Old ethics approval format

Ethics approval(s)

Local ethics approval (Comitato Etico Ospedale Luigi Sacco, Milano, Italy) given on the 1st April 2005 (ref: 125/2005 3)

Study design

Randomised double-blind placebo controlled three-arm parallel study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Human immunodeficiency virus (HIV)

Interventions

Group 1 (n = 20): Double dose; supplementation for 12 weeks plus 4 weeks supplement-free follow up

Group 2 (n = 20): Single dose; supplementation for 12 weeks plus 4 weeks

supplement-free follow up

Group 3 (n = 20): Placebo/control; supplementation for 12 weeks plus 4 weeks supplement-free follow up

Dose regimen: 3 times daily x 16 grams = 48 grams of powder per day (for all three arms). Of these 48 grams, the double dose group received 30 grams of NR100063, the single dose group 15 grams of NR100063. The remainder of the product consisted of inert sugars and maltodextrin. The placebo group received 48 grams of maltodextrin. The powder was to be dissolved in water or juice, or mixed with yoghurt.

Duration of study: 16 weeks

Intervention Type

Drug

Phase

Drug/device/biological/vaccine name(s)

NR100063

Primary outcome(s)

The determination of tolerance and safety during the supplementation period. Blood samples drawn at baseline, week 4, week 12 and week 16 and tolerance was assessed at each visit using recall questionnaire.

Key secondary outcome(s))

To establish the effects of supplementation on biomarkers:

- 1. HIV immune biomarkers
- 2. Gut activity assessed by faecal biomarkers
- 3. Viral load
- 4. CD4 counts

Blood samples drawn at baseline, week 4, week 12 and week 16 and stool samples were collected at baseline and after 12 weeks.

Completion date

08/08/2006

Eligibility

Key inclusion criteria

- 1. Treatment-naïve HIV-positive individuals with no stage 3 illness
- 2. At least 18 years of age
- 3. Males or non-pregnant, non-lactating females
- 4. Never received antiretroviral treatment
- 5. CD4+ T-cell counts between 400 and 800 cells/uL
- 6. Plasma HIV-1 ribonucleic acid (RNA) levels between 1,000 and 65,000 copies/mL

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

Αll

Key exclusion criteria

- 1. Self reported vaccination during the 2 months prior to inclusion, or intention to be vaccinated during study period
- 2. Acute febrile illness
- 3. Current antibiotic use
- 4. Current use of corticosteroids or other immune modulating medications
- 5. Self reported history of IL-2 administration or other vaccine candidates in the past 5 years
- 6. The use of probiotics or fibres in nutritional health products or supplements
- 7. Investigator's uncertainty about the willingness or ability of the patient to comply with the protocol requirements, such as drug or alcohol abuse, mental disorder
- 8. Participation (or intention to participate) in any other studies involving investigational or marketed products concomitantly or within four weeks prior to entry into the study

Date of first enrolment 01/06/2005

Date of final enrolment 08/08/2006

Locations

Countries of recruitment Italy

Study participating centre Ospedale Luigi Sacco Milano Italy 20157

Sponsor information

Organisation

Danone Research B.V. (Netherlands)

ROR

https://ror.org/01c5aqt35

Funder(s)

Funder type

Industry

Funder Name

Danone Research B.V. (Netherlands) - Centre for Specialised Nutrition

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created Date added	Peer reviewed?	Patient-facing?
Results article	results	01/02/2008	Yes	No
Results article	results	01/09/2011	Yes	No
Participant information sheet	Participant information sheet	11/11/2025 11/11/2025	No	Yes